Silhouette MD Review
Appears to have shut downSilhouette MD is closed and is not taking new patients. It charged from $149 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Silhouette MD is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $149/mo. No longer offered.
See our top-rated GLP-1 providers →Silhouette MD sold GLP-1 weight-loss plans through OpenLoop Health. Its site is offline. In October 2026 the domain served a default server page and its program pages returned 404.
Vetted alternatives to Silhouette MD
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Silhouette MD at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $149/mo
- What it included
- Medication · Consult
- FDA status
- No FDA warning letters found
How Silhouette MD scores
Silhouette MD has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something Silhouette MD published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
7.1/10$149/month is 25% below the $199 median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
3.0/10No price appears until the medical intake is finished.
Trust & Safety15%
4.0/10No pharmacy is named for its prescriptions. Its price appears only after the medical intake.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
5.5/10The price covers the medication and clinician visits.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Silhouette MD
Last checked June 2026- Checked the listed price across 4 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Silhouette MD
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Medications Silhouette MD listed
Silhouette MD listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
Lowest advertised tier ('as low as').
Lowest advertised tier ('as low as').
Oral formulation; lowest advertised tier.
Oral formulation; lowest advertised tier.
In its favor
- Semaglutide cost $149 a month, 25% below the $199 median for compounded semaglutide across the sellers we compare
- Tirzepatide cost $299 a month, close to the $269 median for compounded tirzepatide across the sellers we compare
- The monthly price included the medication and clinician visits
- We found no FDA warning letters issued to Silhouette MD
Against it
- It showed a price only after the medical intake, so you could not compare costs before sharing health information
- Not included in the monthly price it charged: coaching
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Silhouette MD is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What Silhouette MD charged
Silhouette MD charged $149/month.
- Compounded semaglutide (injection): $149/month
- Compounded tirzepatide (injection): $299/month
- Compounded semaglutide (oral): $263/month
- Compounded tirzepatide (oral): $325/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so Silhouette MD's $149 is genuinely below the middle, not just advertised that way.
Found, at about $149/month + membership, is the closest like-for-like alternative we review.
What Silhouette MD dispensed
Silhouette MD prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at Silhouette MD at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a proven equal to the shot.
Safety and disclosure
We found no FDA warning letters issued to Silhouette MD. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
Silhouette MD is no longer taking new patients, so the choice is among the sellers that are still open.
The Bottom Line
Silhouette MD is closed and is not taking new patients. It charged from $149 a month.
Where Silhouette MD is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to Silhouette MD sets more sellers in the same category beside Silhouette MD on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Silhouette MD review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of June 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.